The cracks in Medicaid that some experts feared eligible beneficiaries could slip through during the disenrollment process appear to forming, according to a new KFF survey. Many people eligible for Medicaid have not gone through the reenrollment process before. Many others simply aren’t aware that they’re eligible, according to KFF’s review of early data from 11 states. These ...

Apple today announced new health features in iOS 17, iPadOS 17, and watchOS 10, expanding into two impactful areas and providing innovative tools and experiences across platforms. New mental health features allow users to log their momentary emotions and daily moods, see valuable insights, and easily access assessments and resources. iPhone, iPad, and Apple Watch ...

Altarum’s monthly Health Sector Economic Indicators (HSEI) spending series tracks US health care spending and its components on a monthly basis using data released by the Bureau of Economic Analysis and other sources to reflect as closely as possible the categories and spending totals published annually by the Centers for Medicare and Medicaid Services (CMS) in the National ...

Self-insured employers face myriad challenges in trying to manage growing healthcare costs, and one of those results from recent history, according to a survey by the National Alliance of Healthcare Purchaser Coalitions (NAHPC). “Employers are seeing a rise in high-cost claims for younger plan members, with $1 million+ claims disproportionately weighted toward this demographic,” the NAHPC survey ...

Despite the increased adoption of digital health tools and telehealth in the past three years, patients and providers see the “digital front door” as still being a less-than-ideal entry point into healthcare, according to a new Experian Health report. The report is based on a survey (PDF), conducted in December 2022, that reached 202 providers and 1,001 U.S. ...

Biosimilars were supposed to be the catalyst for lower biologics prices, but in the case of insulin products, the leadership now seems to be coming from Medicare and the three dominant insulin producers: Eli Lilly, Novo Nordisk and Sanofi. Following a provision in the Inflation Reduction Act of 2022 that limited the monthly out-of-pocket cost ...